研究論文（114.01～114.12)
| 篇序 | 作者姓名 (順位) |
論文題目 | 發表雜誌名稱 (含年月/卷期/頁次) |
屬性 SCI、SSCI、IEEE |
|---|---|---|---|---|
| 1 | 王憲奕(2) | Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD. | Nephrol Dial Transplant. 2025;40(10):1897-1905. | SCI |
| 2 | 王憲奕(6) | Immune checkpoint inhibitors-associated acute kidney injury: a systematic review and meta-analysis of incidence, kidney recovery, and recurrent risk. | Cancer Immunology, Immunotherapy, 2025, 74(10), 324 | SCI |
| 3 | 王憲奕(5) | Impact of prior COVID-19 vaccination on major adverse kidney events in patients with non-dialysis dependent chronic kidney disease: a global retrospective study. |
Expert Rev Vaccines. 2025;24(1):657-666. |
SCI |
| 4 | 王憲奕(2) | Efficacy, safety, and immunogenicity of UB-851 versus Eprex® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial. | Journal of The Chinese Medical Association | SCI |
| 5 | 簡志強(C) | Outcomes in end-stage renal disease dialysis patients with depression. |
BJPsych Open . 2025 Oct 23;11(6):e250. |
SCI |
| 6 | 江銘彥(C) | Association of serum vitamin D levels and dietary vitamin D intake with latent tuberculosis infection and long-term mortality: a population-based cohort study | BMJ Nutr Prev Health. 2025 Jun 6;8(1):e001213. | SCI |
| 7 | 江銘彥(1) | Association between high-sensitivity troponin and mortality risk in individuals with early kidney disease: A population-based cohort study. | Medicine (Baltimore). 2025 Jun 27;104(26):e43014. | SCI |
| 8 | 江銘彥(5) | Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD | Nephrol Dial Transplant. 2025 Sep 29;40(10):1897-1905. | SCI |
| 9 | 江銘彥(4) | The Kidney Disease Screening and Awareness Program: Transforming Community Outreach and Inspiring Interest in Nephrology. | Clin J Am Soc Nephrol. 2025 May 21;20(8):1150-1153. | SCI |
| 10 | 江銘彥(C) | Association of Gestational Diabetes Mellitus with Cardiometabolic Morbidity and Long-Term Mortality. | Formos J Endocrinol Metab 16: 01-12, 2025 |
非SCI (學會期刊) |
| 11 | 楊翼寧(1) | Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients. | BMC Cancer. 2025;25(1):1900. | SCI |
| 12 | 楊翼寧(1) | Outcomes in end-stage renal disease dialysis patients with depression. | Outcomes in end-stage renal disease dialysis patients with depression. | SCI |
| 13 | 楊翼寧(1) | Comparative effectiveness and prescribing patterns of dapagliflozin vs empagliflozin in type 2 diabetes patients: a target trial emulation. |
Diabetes Res Clin Pract. 2025;228:112427 |
SCI |
| 14 | 楊翼寧(C) | Impact of prior COVID-19 vaccination on major adverse kidney events in patients with non-dialysis dependent chronic kidney disease: a global retrospective study. |
Expert Rev Vaccines. 2025;24(1):657-666. |
SCI |
| 15 | 陳銳溢(1) | Clinical outcomes in people with type 2 diabetes and acute kidney disease: combined SGLT2i and GLP-1RA therapy vs. monotherapy. | Diabetes Research and Clinical Practice, 2025: 112339 | SCI |
| 16 | 陳銳溢(1) | Association of angiotensin receptor-neprilysin inhibitors use and better cardiorenal outcomes in patients with heart failure and acute kidney disease | Cardiovascular drugs and therapy, 2025:1-12 | SCI |
| 17 | 陳銳溢(C) | Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD | Nephrology Dialysis Transplantation, 2025: gfaf064 | SCI |
| 18 | 陳銳溢(C) | Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis. | Journal of the American Heart Association, 2025:14(3), e038714 | SCI |
| 19 | 陳銳溢(1) | Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials | American Journal of Kidney Diseases, 2025 | SCI |
| 20 | 陳銳溢(1) | Clinical outcomes associated with ACE inhibitors and ARBs use in adults older than 85 years who recovered from dialysis‐requiring acute kidney injury | British Journal of Clinical Pharmacology, 2025 | SCI |
| 21 | 陳銳溢(C) | Saline and N-acetylcysteine-based strategies and other approaches to prevent the risk of CA-AKI: a meta-analysis. | Frontiers in Medicine, 2025, 12, 1608626 | SCI |
| 22 | 陳銳溢(C) | Immune checkpoint inhibitors-associated acute kidney injury: a systematic review and meta-analysis of incidence, kidney recovery, and recurrent risk | Cancer Immunology, Immunotherapy, 2025, 74(10), 324 | SCI |
| 23 | 陳銳溢(C) | Discontinuation versus continuation of renin–angiotensin system inhibitors in chronic kidney disease stage 3–5 patients: a systematic review and meta-analysis. | Frontiers in Pharmacology, 2025, 16, 1646969 | SCI |
| 24 | 陳銳溢(C) | Clinical outcomes after immune checkpoint inhibitor-associated acute kidney injury: a cohort study. | BMJ open, 2025, 15(2), e092752 | SCI |
| 25 | 陳銳溢(2) | Trajectories of urea‑to‑creatinine ratio and risk of clinical outcomes in survivors of acute kidney disease: a population-based study. | Clinical Kidney Journal, 2025:18(6), sfaf175 | SCI |
| 26 | 陳銳溢(2) | Potential benefits of GLP-1 receptor agonist in dialysis patients with type 2 diabetes: the need for comprehensive pharmacokinetic and hemodialysis analyses | Cardiovascular Diabetology, 2025:24(1), 110 | SCI |
| 27 | 陳銳溢(2) | Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients | Cardiovascular Diabetology, 2025:24(1), 87 | SCI |
| 28 | 陳銳溢(5) | Exploring the high prevalence, comorbidities, and indicators of mild autonomous cortisol secretion in primary aldosteronism: a cohort study and systematic review | Hypertension Research, 2025, 1-14 | SCI |
| 29 | 陳銳溢(3) | Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation | Nature Communications, 2025, 16(1), 9641 | SCI |
| 30 | 陳銳溢(3) | Enhanced outcomes in type 2 diabetes patients with acute kidney disease through thiazolidinedione | The Journal of Clinical Endocrinology & Metabolism, 2025, 110(8), 2205-2214 | SCI |
| 31 | 陳銳溢(4) | Dipeptidyl peptidase 4 inhibitors reduce the risk of adverse outcomes after acute kidney injury in diabetic patients | Clinical Kidney Journal, 2025, 18(2), sfae385 | SCI |
| 32 | 陳銳溢(C) | Effectiveness and Safety of Dialyzable versus Nondialyzable Beta-Blockers in Patients with Maintenance Hemodialysis: A Retrospective Cohort Study | Acta Nephrologica/臺灣腎臟醫學會雜誌, 2025 | Non-SCI |
| 33 | 黃筠婷(6) | Cardio-Kidney Outcomes for Combined versus Monotherapy with Finerenone or SGLT2 Inhibitors in Patients with CKD |
Nephrol Dial Transplant. 2025 Sep 29;40(10):1897-1905 |
SCI |
| 34 | 莊閔翔(1) | Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD | Nephrol Dial Transplant. 2025;40(10):1897-1905. | SCI |